Powered by OpenAIRE graph
Found an issue? Give us feedback
image/svg+xml art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos Open Access logo, converted into svg, designed by PLoS. This version with transparent background. http://commons.wikimedia.org/wiki/File:Open_Access_logo_PLoS_white.svg art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos http://www.plos.org/ International Journa...arrow_drop_down
image/svg+xml art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos Open Access logo, converted into svg, designed by PLoS. This version with transparent background. http://commons.wikimedia.org/wiki/File:Open_Access_logo_PLoS_white.svg art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos http://www.plos.org/
International Journal of Nanomedicine
Article . 2025 . Peer-reviewed
License: CC BY NC
Data sources: Crossref
image/svg+xml art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos Open Access logo, converted into svg, designed by PLoS. This version with transparent background. http://commons.wikimedia.org/wiki/File:Open_Access_logo_PLoS_white.svg art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos http://www.plos.org/
image/svg+xml art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos Open Access logo, converted into svg, designed by PLoS. This version with transparent background. http://commons.wikimedia.org/wiki/File:Open_Access_logo_PLoS_white.svg art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos http://www.plos.org/
PubMed Central
Conference object . 2025
License: CC BY NC
Data sources: PubMed Central
image/svg+xml art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos Open Access logo, converted into svg, designed by PLoS. This version with transparent background. http://commons.wikimedia.org/wiki/File:Open_Access_logo_PLoS_white.svg art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos http://www.plos.org/
Dove Medical Press
Review . 2025 . Peer-reviewed
Data sources: Dove Medical Press
versions View all 4 versions
addClaim

Nanocomposites to Overcoming Sorafenib Resistance in Hepatocellular Carcinoma Therapy

Authors: Jie Liu; Shizhao Zhou; Yingying Wei; Jinglei Du; Fan Jia; Wenhui Dong; Yangyi Cao; +4 Authors

Nanocomposites to Overcoming Sorafenib Resistance in Hepatocellular Carcinoma Therapy

Abstract

The emergence of drug resistance is the major obstacle to the clinical application of sorafenib (SOR), which often leads to disease progression, recurrence, and even death in hepatocellular carcinoma (HCC) patients. Nanocomposite-mediated drug delivery enhances targeting precision and therapeutic utilization efficiency. Nanocomposites constructed by nanoparticles (NPs) and various therapeutic components have emerged as effective approaches to enhance HCC therapeutic efficacy. Designing based on the mechanisms underlying SOR resistance, specially engineered nanocomposites can be designed to overcome SOR resistance. This review aims to highlight the advantages of nanocomposites in overcoming HCC SOR resistance. First, the various SOR resistance mechanisms that have been identified so far are briefly outlined. Second, the construction methods and characteristics of nanocomposites designed to overcome SOR resistance are summarized and categorized according to different types of NPs. Subsequently, the roles and therapeutic effects of nanocomposites in SOR-resistant HCC are analyzed, primarily including remodeling the tumor microenvironment (TME), restoring normal epigenetic regulation, improving drug metabolism, and inhibiting abnormally activated signaling molecules and pathways. Finally, the advantages and disadvantages of nanocomposites used to reverse drug resistance are discussed, and their development direction in future research is prospected, which provide new approaches for developing advanced nanocomposites to overcome SOR resistance.

Related Organizations
Keywords

Carcinoma, Hepatocellular, Liver Neoplasms, Antineoplastic Agents, Review, Sorafenib, Nanocomposites, Drug Delivery Systems, International Journal of Nanomedicine, Drug Resistance, Neoplasm, Tumor Microenvironment, Humans, Animals

  • BIP!
    Impact byBIP!
    selected citations
    These citations are derived from selected sources.
    This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
    0
    popularity
    This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.
    Average
    influence
    This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
    Average
    impulse
    This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.
    Average
Powered by OpenAIRE graph
Found an issue? Give us feedback
selected citations
These citations are derived from selected sources.
This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
BIP!Citations provided by BIP!
popularity
This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.
BIP!Popularity provided by BIP!
influence
This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
BIP!Influence provided by BIP!
impulse
This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.
BIP!Impulse provided by BIP!
0
Average
Average
Average
Green
gold